



Sabin cAd3-Marburg Vaccine Program Overview

Kelly Lyn Warfield, Ph.D.

President, Research and Development

Jan 15, 2025

The work described in this presentation was funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contracts 75A50119C00055 and 75A50123C00010 and separately via MCDC Contract #2019-507. The contract and federal funding are not an endorsement of the study results, product or company.

cAd3-Marburg Vaccine Status

- Completed multiple preclinical studies (157 MARV-vaccinated NHPs)
 - Demonstrated rapid and durable responses:
 - Onset of protection by 3 days (60%) and 100% within 7 days
 - Durability: 100% protection at 6 months; 75% at 1 year
 - Identified candidate correlate of protection: GP-binding Ab
- Existing Inventory of GMP Bulk Drug Substance and Final Drug Product
- Phase 1 clinical trials completed (56 humans)
 - Safe (no SAEs) and Immunogenic
- Phase 2 clinical trials underway
- Anticipate following Animal Rule Pathway for U.S. FDA licensure

cAd3-Marburg Vaccine Phase 2 Clinical Trials

Study	Sabin-002: Phase 2 RCT in Kenya and Uganda	Sabin-004: Phase 2 RCT in US
Participants	125 healthy adults, 18-70 years	~200 healthy adults, 18-70 years
Locations	Kampala, Uganda (Makerere University Walter Reed Project) Siaya, Kenya (Kenya Medical Research Institute, CRDR, Siaya)	4 geographically diverse sites in US
Arms (4:1)	Group 1: Single Dose of cAd3-Marburg Vaccine (1×10^{11} PU) via intramuscular injection Group 2: Single Dose of placebo (0.9% NaCl solution for injection) via intramuscular injection	
Status	One year follow-up visits ongoing	FPFV expected mid-Feb 2025
Registration	NCT05817422/PACTR202306534727467	NCT06620003

Study	RBC-001, Part A: Phase 2 Rapid Response, Open-Label Study to Assess Safety and Immunogenicity of Investigational Monovalent Chimpanzee Ad-Vectored Marburg Vaccine in Adults in an Outbreak Setting
Sponsor	Rwanda Biomedical Centre
Participants	Health care providers, front-line workers, 'red ring' contacts, ≥ 18 years
Arms	Single Dose of cAd3-Marburg Vaccine (1×10^{11} PU) IM
Status	1710 subjects enrolled. DSMB has reviewed study data twice and agreed with continuation of the study. One Treatment Center HCW vaccinated on Oct 9 was later confirmed Marburg positive*.
Registration	PACTR202412708603314

*Vaccinated HCW developed Marburg Virus Disease had mild symptoms and was discharged on Oct 30; considered unrelated to cAd3-Marburg Vaccine, as exposure reported prior to vaccination